VERU

Veru Inc.

1.18 USD

Last updated Dec 10, 17:15 UTC

Yesterday HIGH

$1.23

Yesterday LOW

$1.14

52w HIGH

$6.57

52w LOW

$0.66

EPS

-0.13

PE

-9.08

Next Earnings

Dec 22, 2023

Overview News Insider Transactions Government Trades

Veru Inc. stock is up 28.26% since 30 days ago. The next earnings date is Dec 22, 2023. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 24 December’s closed higher than November.

Veru Inc. focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company was formerly known as The Female Health Company.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Miami, United States Of America

Website

verupharma.com

Benzinga Insights

Thu May 11, 2023

Earnings Scheduled For May 11, 2023

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its first quarter.
Benzinga Insights

Thu May 11, 2023

Veru: Q2 Earnings Insights
Benzinga Newsdesk

Thu May 11, 2023

Veru Q2 EPS $(0.48) Misses $(0.33) Estimate, Sales $6.59M Beat $4.32M Estimate

Veru (NASDAQ:VERU) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.33) by 45.45 percent. This is a 166.67 percent decrease over losses of $(0.18) per share from the same
Benzinga Insights

Wed May 10, 2023

A Preview Of Veru's Earnings
Benzinga Insights

Mon May 8, 2023

Analyst Ratings for Veru
richadhand@benzinga.com

Mon May 8, 2023

HC Wainwright & Co. Reiterates Buy on Veru, Maintains $6 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Veru (NASDAQ:VERU) with a Buy and maintains $6 price target.
Happy Mohamed

Thu May 4, 2023

Veru Reaches Agreement With FDA On Confirmatory Phase 3 Clinical Trial For Sabizabulin Treatment Of Hospitalized COVID-19 Adult Patients At High Risk For ARDS

Reached agreement with FDA on confirmatory Phase 3 clinical trial design in 408 subjects with primary endpoint of all-cause mortality at Day 60 Study to expand treatment population to include all WHO-4, WHO-5,
Benzinga Newsdesk

Wed May 3, 2023

Veru Inc Files For Offering Of Up To $100M Of Shares Of Common Stock; Says In Addition, Additional $2M Of Shares Of Common Stock Issued As Commitment Shares To Lincoln Park Capital Fund

- Sec Filing
Benzinga Newsdesk

Wed May 3, 2023

Veru Enters Into Common Stock Purchase Agreement Up To $100M With Lincoln Park Capital Fund At Sole Discretion From Time To Time Over 36-Month Period
Christopher Sappo

Thu Apr 27, 2023

Short Interest Sector Focus: Healthcare Sector

As of the close of business on Wednesday, 4/26, we captured the Top 10 Highest Short Interest % stocks within the Healthcare sector. The average short interest for stocks within the Healthcare sector stands at 3.14%. Therefore, the below stocks are showing a more pessimistic outlook than their peers within the respective sector.

Rankowitz Michael L, Director

Mon Oct 2, 2023

VERU Recent Insider Trades and Stock Chart

90,000 shares awarded
Eisenberger Mario, Director

Mon Oct 2, 2023

VERU Recent Insider Trades and Stock Chart

70,000 shares awarded
Lu Lucy, Director

Mon Oct 2, 2023

VERU Recent Insider Trades and Stock Chart

80,000 shares awarded
Hyun Grace, Director

Mon Oct 2, 2023

VERU Recent Insider Trades and Stock Chart

60,000 shares awarded